Allosteric integrase inhibitor - Open Access .click

Results 61 to 70 of about 1,267 (159)

Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review

Reviews in Medical Virology, Volume 34, Issue 2, March 2024.
Abstract The discovery of anti‐retroviral (ARV) drugs over the past 36 years has introduced various classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non‐nucleoside reverse transcriptase inhibitors, protease inhibitor, fusion, and integrase strand transfer inhibitors inhibitors.
Nursyuhada Azzman +6 more
wiley +1 more source

Exploring Lead‐Like Molecules of Traditional Chinese Medicine for Treatment Quest against Aliarcobacter butzleri: In Silico Toxicity Assessment, Dynamics Simulation, and Pharmacokinetic Profiling

BioMed Research International, Volume 2024, Issue 1, 2024.
Background. Aliarcobacter butzleri is a Gram‐negative, curved or spiral‐shaped, microaerophilic bacterium and causes human infections, specifically diarrhea, fever, and sepsis. The research objective of this study was to employ computer‐aided drug design techniques to identify potential natural product inhibitors of a vital enzyme in this bacterium ...
Zarrin Basharat +5 more
wiley +1 more source

Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage [PDF]

Retrovirology, 2013
Abstract Background LEDGF/p75 (LEDGF) is the main cellular cofactor of HIV-1 integrase (IN). It acts as a tethering factor for IN, and targets the integration of HIV in actively transcribed gene regions of chromatin. A recently developed class of IN allosteric inhibitors can inhibit the LEDGF-IN interaction.
Le Rouzic, Erwann +21 more
openaire +2 more sources

A Critical Role of the C-terminal Segment for Allosteric Inhibitor-induced Aberrant Multimerization of HIV-1 Integrase [PDF]